肝动脉化疗栓塞术联合阿帕替尼治疗中晚期肝癌的临床观察  

Clinical observation of transcatheter arterial chemoembolization combined with apatinib in patients with advanced hepatocellular carcinoma

作　　者：隋永博[1] 陈金玲 张重阳[1] 王宇 周立芳[1] SUI Yong-bo;CHENG Jin-ling;ZHANG Chong-yang;ZHOU Li-fang(First Department of Hepatobiliary Surgery,Cangzhou Integrated Traditional Chinese and Western Medicine Hospital of Hebei province,Cangzhou Hebei,061000,China)

机构地区：[1]河北省沧州中西医结合医院肝胆外一科,河北沧州061000

出　　处：《中西医结合肝病杂志》2024年第2期123-125,共3页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：河北省2023年度医学科学研究课题计划(No.20232146)。

摘　　要：目的:探讨肝动脉化疗栓塞术(TACE)联合阿帕替尼对中晚期肝癌患者的治疗效果,及对其客观缓解率、生存时间和免疫功能的影响。方法:选用2020年1月至2021年6月接受治疗的100例中晚期肝癌患者为研究对象,随机分为联合组和对照组,每组各50例。对照组患者在常规治疗的基础上采用TACE术进行治疗,联合组患者在对照组的基础上加用阿帕替尼治疗。比较两组患者治疗后疾病客观缓解率、生存时间、免疫功能及不良反应发生情况。结果:治疗后,联合组患者客观缓解率(50.00%)较对照组(28.00%)明显提高(P<0.05);联合组患者中位总生存期(OS)、中位无进展生存期(PFS)较对照组显著增加(P<0.05);治疗后联合组患者CD4^(+)、CD4^(+)/CD8^(+)水平较对照组明显升高(P<0.05),CD8^(+)水平较对照组明显降低(P<0.05);两组患者不良反应发生情况差异无统计学意义(P>0.05)。结论:对中晚期肝癌患者采用TACE与阿帕替尼联合治疗,临床效果较为理想。Objective:To investigate the efficacy of transarterial chemoembolisation(TACE)combined with apatinib in the treatment of mid to late stage liver cancer patients,and its impacts on objective response rate,survival time,and immune function.Methods:A total of 100 patients with advanced liver cancer who received treatment in our hospital from January 2020 to June 2021 were selected as the study subjects.They were randomly divided into combined group and control group,50 cases in each group.The patients in the control group were treated with TACE on the basis of conventional treatment,and the patients in the combined group were treated with apatinib on the basis of the control group.The objective remission rate,survival time,immune function and adverse reactions were compared between the two groups after treatment.Results:After treatment,the objective response rate of the combination group(50.00%)was obviously higher than that of the control group(28.00%)(P<0.05).Compared with the control group,the median overall survival time(OS)and median progression free survival time(PFS)in the combined group were obviously higher(P<0.05).After treatment,the immune function indicators of the two groups were compared,the levels of CD4^(+)and CD4^(+)/CD8^(+)in the combination group were obviously higher than those in the control group(P<0.05),while the level of CD8^(+)was obviously lower than that in the control group(P<0.05).There was no obvious difference in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion:The combination therapy of TACE and apatinib is effective and has high clinical application value for patients with mid to late stage liver cancer.

关 键 词：肝癌 肝动脉化疗栓塞术 阿帕替尼 客观缓解率 免疫功能 生存时间 

分 类 号：R735.7[医药卫生—肿瘤]